Home >
Medicine Info >
Glimigen-MV1 Tablet
Loading interface...

Glimigen-MV1 Tablet

Manufactured byEKARD LIFE SCIENCES PVT LTD
ContainsGlimepiride (1 mg) + Metformin (500 mg) + Voglibose (0.2 mg)
Description
Glimigen-MV1 Tablet is a combination of Glimepiride, Metformin and Voglibose. It is an anti-diabetic medicine used for the treatment of type 2 diabetes in adults. It works by increasing insulin release and improving your body's response to insulin (a hormone that enables your body to use sugar). It also prevents the breakdown of carbohydrates to glucose (sugar) and thereby lowers your blood sugar levels. Glimigen-MV1 Tablet may result in low blood sugar levels and you may feel hungry, irritable, confused, or anxious. It is always recommended to eat or drink a fast-acting source of sugar (fruit juice, candy, raisins, etc.) to quickly treat these symptoms. Other common side effects include headache, dizziness, nausea, diarrhoea, etc. Consult your doctor if these symptoms persist or if they become severe. Glimigen-MV1 Tablet should be taken exactly as advised by your doctor. Take it at the same time every day to maintain a constant level of this medicine in your body. Do not skip a dose or discontinue the treatment as it may cause an increase in your blood sugar levels. Glimigen-MV1 Tablet is not recommended if you are allergic to it. Inform your doctor if you have kidney, liver, or heart problems before beginning the treatment. This medicine is not recommended for use in children and adolescents below 18 years of age. Consult your doctor if you are pregnant, planning a pregnancy, or are breastfeeding.
QUICK LINKS:
Side effectsConcernsUsage

Side effects

Major & minor side effects for Glimigen-MV1 Tablet

  • Headache
  • Dizziness
  • Weakness
  • Nausea
  • Low blood sugar levels (hypoglycaemia)
  • Stomach upset
  • Diarrhoea
  • Change in taste
  • Flatulence (Passing of gas)

Uses of Glimigen-MV1 Tablet

What is it prescribed for?

  • Type II Diabetes Mellitus
Read More
Concerns

Commonly asked questions

  • How long does it take for this medicine to take effect?
    The time required for Glimigen-MV1 Tablet to show its action is not clinically known.
  • How long do the effects of this medicine last?
    The duration for which Glimigen-MV1 Tablet remains active in your body is not clinically known.
  • Is it safe to consume alcohol while taking this medicine?
    Consumption of alcohol is not recommended during treatment with Glimigen-MV1 Tablet as it may increase the risk of lactic acidosis (increased blood lactic acid levels). It may also affect the ability of this medicine to control your blood sugar levels.
  • Is this a habit forming medicine?
    No habit-forming tendencies have been reported with Glimigen-MV1 Tablet.
  • Can this medicine be taken during pregnancy?
    Due to a lack of sufficient safety and efficacy data, Glimigen-MV1 Tablet is not recommended for use in pregnancy. Consult your doctor if you are pregnant or planning a pregnancy.
  • Can this medicine be taken while breast-feeding?
    Glimigen-MV1 Tablet may passes into breastmilk. This medicine is not recommended while breastfeeding due to the increased risk of hypoglycaemia (low blood sugar levels) in your infant. Consult your doctor if you are breastfeeding.

Allergy

Avoid taking Glimigen-MV1 Tablet if you are allergic to it. However, seek immediate medical attention if you notice any symptoms such as skin rash, itching/swelling (especially of your face/tongue/throat), severe dizziness, breathing difficulty, etc.

Type 1 Diabetes mellitus

Type 1 diabetes, also known as insulin-dependent diabetes, is a chronic condition in which the pancreas produces little or no insulin. Symptoms include increased thirst, frequent urination, hunger, fatigue, and blurred vision. Glimigen-MV1 Tablet is not recommended if you have type 1 diabetes mellitus.

Metabolic Acidosis

Metabolic acidosis is characterized by high levels of acids in your blood. The symptoms include thirst, frequent urination, vomiting, abdominal pain, weakness, muscle cramps, etc. Glimigen-MV1 Tablet is not recommended if you have metabolic acidosis as this medicine may worsen your condition.

Liver impairment

Liver impairment is the loss of liver function. Glimigen-MV1 Tablet is not recommended if you have liver problems due to increased risk of severe side effects.

Severe kidney impairment

Kidney impairment is the loss of kidney function. Glimigen-MV1 Tablet is not recommended if you have severe kidney problems as it may cause complications such as lactic acidosis (acid build up in the blood).
Warnings for special population

Pregnancy

Due to a lack of sufficient safety and efficacy data, Glimigen-MV1 Tablet is not recommended for use in pregnancy. Consult your doctor if you are pregnant or planning a pregnancy.

Breast-feeding

Glimigen-MV1 Tablet may passes into breastmilk. This medicine is not recommended while breastfeeding due to the increased risk of hypoglycaemia (low blood sugar levels) in your infant. Consult your doctor if you are breastfeeding.
General warnings

Hypoglycaemia (Low blood sugar levels)

Glimigen-MV1 Tablet may cause hypoglycaemia. Regular monitoring of your blood sugar levels is recommended. Your doctor may advise you to carry a sugar candy to counteract the effects of low blood sugar levels when necessary.

Surgery

Glimigen-MV1 Tablet is not recommended to be used during surgery due to the increased risk of lactic acidosis (high levels of lactic acid in the blood). If you are taking this medicine, inform your doctor before undergoing any surgery. Your doctor may suggest you discontinue the treatment before surgery.

Use in children

Glimigen-MV1 Tablet is not recommended for use in children and adolescents below 18 years of age due to a lack of safety and efficacy data.

Driving or operating machines

Glimigen-MV1 Tablet may cause low blood sugar levels and dizziness which may affect your mental alertness. Avoid driving or operating machines if you experience these symptoms after taking this medicine.

Other medicines

Glimigen-MV1 Tablet may increase your risk of sleepiness and impaired thinking when taken with medicines that have a sedative effect. Inform your doctor about all your current medicines including any herbs or supplements before beginning treatment with this medicine.

Missed Dose

Try not to skip a dose of Glimigen-MV1 Tablet. Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed one. Do not double the dose to compensate for a missed one.

Overdose

Do not take excess dose than prescribed by your doctor. Contact your doctor in case of an overdose with Glimigen-MV1 Tablet.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

N/A

Instructions

Consumption of alcohol is not recommended during treatment with Glimigen-MV1 Tablet as it may increase the risk of lactic acidosis (increased blood lactic acid levels). It may also affect the ability of this medicine to control your blood sugar levels.
Interaction with Medicine

Estradiol

Miconazole

Corticosteroids

Insulin

Iodinated Contrast Media

Fluoroquinolone antibiotics

Fluconazole

ACE inhibitors

Disease interactions

Vitamin B12 deficiency

Glimigen-MV1 Tablet should be used with caution if you have vitamin B12 deficiency. This medicine interferes with the absorption of Vitamin B12 in your body. Consult your doctor if you are taking these medications together.

Heart disease

Glimigen-MV1 Tablet should be used with caution if you have any pre-existing heart problems due to the increased risk of worsening your condition. Close monitoring of your heart function and vital signs is recommended.

Hemolytic Anemia/G6PD Deficiency

Glucose--6-phosphate dehydrogenase (G6PD) deficiency is a genetic condition in which your red blood cells break down when exposed to certain medicines, infections, or stress. Glimigen-MV1 Tablet is not recommended if you have this condition as it may result in haemolytic anaemia (low red blood cell count).
Food interactions
Information not available.
Lab interactions
Information not available.
This is not an exhaustive list of possible drug interactions. You should consult your doctor about all the possible interactions of the drugs you’re taking.
Take Glimigen-MV1 Tablet with food or as prescribed by your doctor. Avoid taking more than the prescribed dose as it may increase the risk of side effects. Avoid the discontinuation of Glimigen-MV1 Tablet without consulting your doctor. Your doctor may suggest regular monitoring of your blood sugar levels to check that your diabetes is under control. Regular follow-up visits with your doctor are recommended to evaluate your condition. Maintain a proper diet and do regular exercise to get maximum benefits of the treatment.
Miscelleneous

To be taken with food

To be taken as instructed by doctor

May cause sleepiness

How it works
Glimigen-MV1 Tablet is a combination of Glimepiride, Metformin and Voglibose. Glimepiride works by increasing the secretion of insulin (a hormone that enables your body to use sugar) from the pancreas and also improves the body's ability to use insulin efficiently. This helps in controlling blood sugar levels. Metformin works by improving the body’s response to insulin and decreasing glucose (sugar) production in the liver. This helps in lowering the increased blood sugar levels. Voglibose works by reducing the blood glucose level by preventing the breakdown of large carbohydrates into glucose. This combination is thus effective in reducing blood sugar levels.
Legal Status

Unknown

Unknown

Unknown

Unknown

Classification

Category

Sulfonylureas, Oral Biguanides, Alpha-glucosidase inhibitors, Oral anti-diabetic combinations

Schedule

Schedule H

Medicines.org.uk. 2021. Glimepiride 2 mg Tablets - Summary of Product Characteristics (SmPC) - (emc). [online] Available at: < [Accessed 17 September 2021].

https://www.medicines.org.uk/emc/product/6048/smpc#gref>

Medicines.org.uk. 2021. Metformin 500mg tablets - Summary of Product Characteristics (SmPC) - (emc). [online] Available at: < [Accessed 17 September 2021].

https://www.medicines.org.uk/emc/product/594/smpc#gref>

Medicines.org.uk. 2021. [online] Available at: < [Accessed 17 September 2021].

https://www.medicines.org.uk/emc/files/pil.6048.pdf>

Medicines.org.uk. 2021. [online] Available at: < [Accessed 17 September 2021].

https://www.medicines.org.uk/emc/files/pil.594.pdf>

Drugs, H., 2021. Glimepiride: MedlinePlus Drug Information. [online] Medlineplus.gov. Available at: < [Accessed 17 September 2021].

https://medlineplus.gov/druginfo/meds/a696016.html>

Drugs, H., 2021. Metformin: MedlinePlus Drug Information. [online] Medlineplus.gov. Available at: < [Accessed 17 September 2021].

https://medlineplus.gov/druginfo/meds/a696005.html>

Pubchem.ncbi.nlm.nih.gov. 2021. Voglibose. [online] Available at: < [Accessed 17 September 2021].

https://pubchem.ncbi.nlm.nih.gov/compound/Voglibose>
Loading related questions...
Something doesn’t feel right?
Report an error

Information on this page was last updated on 20 Oct 2021

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.